Our in vitro assays demonstrate a correlation between target expression level and activity of the molecule, suggesting that MM with gain of 1q21 may be exquisitely sensitive to the anti-FcRH5/CD3 TDB, thus providing clinical benefit to a patient population that otherwise has very limited treatment options. This evidence concerns the gene FCRL5 and Miyoshi myopathy.